Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE

Byeong Keuk Kim, Seungjin Oh, Dong Woon Jeon, Joo Young Yang, Jung Sun Kim, Sungha Park, Donghoon Choi, Yangsoo Jang, Bum Kee Hong, Hyuk Moon Kwon, Seung Whan Lee, Choong Won Goh, Kihwan Kwon, Sung Kee Ryu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411-419)

Original languageEnglish
Pages (from-to)411-419
Number of pages9
JournalJournal of Interventional Cardiology
Volume22
Issue number5
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Sirolimus
Angioplasty
Chronic Kidney Failure
Stents
Registries
Thrombosis
Metals
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Byeong Keuk ; Oh, Seungjin ; Jeon, Dong Woon ; Yang, Joo Young ; Kim, Jung Sun ; Park, Sungha ; Choi, Donghoon ; Jang, Yangsoo ; Hong, Bum Kee ; Kwon, Hyuk Moon ; Lee, Seung Whan ; Goh, Choong Won ; Kwon, Kihwan ; Ryu, Sung Kee. / Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease : Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE. In: Journal of Interventional Cardiology. 2009 ; Vol. 22, No. 5. pp. 411-419.
@article{8770e5f9edbd403b98f65d81c8176304,
title = "Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE",
abstract = "Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24{\%}) was nearly similar with that of the BMS-ESRD group (24{\%}, P = 1.000). The 3-year rates of death (26{\%} vs. 24{\%}, P = 0.824) or MACE (37{\%} vs. 43{\%}, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9{\%}), compared with BMS-ESRD (24{\%}, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17{\%} vs. 14{\%}, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15{\%}) versus BMS-ESRD group (10{\%}, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411-419)",
author = "Kim, {Byeong Keuk} and Seungjin Oh and Jeon, {Dong Woon} and Yang, {Joo Young} and Kim, {Jung Sun} and Sungha Park and Donghoon Choi and Yangsoo Jang and Hong, {Bum Kee} and Kwon, {Hyuk Moon} and Lee, {Seung Whan} and Goh, {Choong Won} and Kihwan Kwon and Ryu, {Sung Kee}",
year = "2009",
month = "10",
day = "1",
doi = "10.1111/j.1540-8183.2009.00495.x",
language = "English",
volume = "22",
pages = "411--419",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "5",

}

Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease : Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE. / Kim, Byeong Keuk; Oh, Seungjin; Jeon, Dong Woon; Yang, Joo Young; Kim, Jung Sun; Park, Sungha; Choi, Donghoon; Jang, Yangsoo; Hong, Bum Kee; Kwon, Hyuk Moon; Lee, Seung Whan; Goh, Choong Won; Kwon, Kihwan; Ryu, Sung Kee.

In: Journal of Interventional Cardiology, Vol. 22, No. 5, 01.10.2009, p. 411-419.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease

T2 - Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE

AU - Kim, Byeong Keuk

AU - Oh, Seungjin

AU - Jeon, Dong Woon

AU - Yang, Joo Young

AU - Kim, Jung Sun

AU - Park, Sungha

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Hong, Bum Kee

AU - Kwon, Hyuk Moon

AU - Lee, Seung Whan

AU - Goh, Choong Won

AU - Kwon, Kihwan

AU - Ryu, Sung Kee

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411-419)

AB - Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411-419)

UR - http://www.scopus.com/inward/record.url?scp=70349741104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349741104&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8183.2009.00495.x

DO - 10.1111/j.1540-8183.2009.00495.x

M3 - Article

C2 - 19702679

AN - SCOPUS:70349741104

VL - 22

SP - 411

EP - 419

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 5

ER -